
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">



<html xmlns="http://www.w3.org/1999/xhtml">
<head id="ctl00_ctl00_Head1"><title>
	DPT Website
</title><link href="/w3c/p3p.xml" rel="P3Pv1" /><meta http-equiv="Content-Type" content="text/html; charset=UTF-8" /><meta name="Description" content="CSAT's Division of Pharmacologic Therapies (DPT). Medication-Assisted Treatment for Substance Use Disorders." /><link href="../../styles/dpt.css" rel="stylesheet" type="text/css" media="screen" /><link href="../../styles/print.css" rel="stylesheet" type="text/css" media="print" /><link rel="shortcut icon" href="../../favicon.ico" />
    <!--<link id="ctl00_Link2" rel="icon" href="../../favicon.ico" type="image/x-icon" />-->
</head>
<body style="margin: 0px 0px 0px 0px; padding: 0px 0px 0px 0px;">
    <table align="center" cellspacing="0" cellpadding="0" style="background-color: #ffffff;
        width: 800px;">
        <tr>
            <td>
                <div title="medication-assisted treatment for substance use disorders">
                    <div>
                        <table width="100%" border="0" summary="table is used for layout purposes only."
                            cellspacing="0" cellpadding="0" style="background-color: #2d4a72" class="printHeader1">
                            <tr>
                                <td align="left" valign="bottom" style="height: 115px">
                                    <img src="../../images/dptheader.gif" id="ctl00_Img1" alt="medication-assisted treatment for substance use disorders" border="0" align="left" usemap="#map" class="printHeader1" /></td>
                            </tr>
                            
                        </table>
                    </div>
                    <div id="topnav2">
                        <ul id="nav">
                            <li><a href="../../index.aspx" id="ctl00_a1" title="dpt home page" accesskey="h">
                                home</a></li>
                            <li>&nbsp;&#149;&nbsp;</li>
                            <li><a href="../../regulations/regindex.aspx" id="ctl00_a4" title="regulations" accesskey="r">regulations</a></li>
                            <li>&nbsp;&#149;&nbsp;</li>
                            <li><a href="../medsindex.aspx" id="ctl00_a2" title="pharmacotherapy" accesskey="m">pharmacotherapy</a></li>
                            <li>&nbsp;&#149;&nbsp;</li>
                            <li><a href="../../comor/comorindex.aspx" id="ctl00_a3" title="comorbidities" accesskey="b">co-morbidities</a></li>
                            <li>&nbsp;&#149;&nbsp;</li>
                            <li><a href="../../treatment/treatmentindex.aspx" id="ctl00_a5" title="find" accesskey="f">find treatment</a> </li>
                            <li>&nbsp;&#149;&nbsp;</li>
                            <li><a href="../../patients/patientsindex.aspx" id="ctl00_a6" title="patients" accesskey="t">patient resources</a></li>
                            <li>&nbsp;&#149;&nbsp;</li>
                            <li><a href="../../providers/providerindex.aspx" id="ctl00_a7" title="providers" accesskey="v">provider resources</a></li>
                        </ul>
                    </div>
                </div>
                <table width="100%" style="vertical-align: top;" class="printpage">
                    <tr>
                        <td class="noprint" style="width: 215px; vertical-align: top; border-style: solid; border-width: 1px;
                            border-right-color: #FFCC66; border-top-color: White; border-bottom-color: White;
                            border-left-color: White;">
                            <table style="width: 215px; vertical-align: top">
                                <tr>
                                    <td valign="top">
                                        <div id="search" class="search" style="width: 100%;">
                                            <form action="http://search2.samhsa.gov/search?" id="searchDPT" method="get" style="margin-bottom: 5px;">
                                                <input type="text" size="19" name="q" id="q" style="height: 18px; font-size: 11px;" />&nbsp;
                                                <label for="q">
                                                    <input src="../../images/go_button.gif" name="ctl00$ctl00" type="image" style="border: 0;
                                                        height: 28px; width: 53px;" alt="Search" onclick="this.form.target='_blank';" /></label>
                                                <input value="date:D:L:d1" name="sort" type="hidden" />
                                                <input value="xml_no_dtd" name="output" type="hidden" />
                                                <input value="UTF-8" name="ie" type="hidden" />
                                                <input value="UTF-8" name="oe" type="hidden" />
                                                <input value="DPT" name="client" type="hidden" />
                                                <input value="DPT" name="proxystylesheet" type="hidden" title="Search" />
                                                <input value="DPT" name="site" type="hidden" title="Search" />
                                                <a class="searchlink" href="http://search2.samhsa.gov/search?access=p&amp;output=xml_no_dtd&amp;sort=date%3AD%3AL%3Ad1&amp;site=DPT&amp;ie=UTF-8&amp;btnG=search&amp;client=DPT&amp;oe=UTF-8&amp;proxystylesheet=DPT&amp;proxycustom=&amp;lt;ADVANCED/&amp;gt;">
                                                    Advanced Search</a> | <a class="searchlink" href="http://www.samhsa.gov/search_help.aspx"
                                                        onclick="this.form.target='_blank';">Help</a>
                                            </form>
                                        </div>
                                        <div id="leftnav" style="width: 100%; height: auto;">
                                            <ul id="leftnavContent">
                                                <li><a href="../../regulations/regindex.aspx">Opioid Treatment Regulation</a>
                                                    <ul>
                                                        <li><a href="../../regulations/accreditation.aspx">Accreditation</a></li>
                                                        <li><a href="../../regulations/certification.aspx">Certification</a></li>
                                                        <li><a href="../../regulations/exrequests.aspx">Exception Requests</a></li>
                                                        <li><a href="http://buprenorphine.samhsa.gov/" onclick='alert("You are about to leave the DPT Web site. The page you have requested will open in a new window. Close the new window to return to the DPT Web site.");'
                                                            target='_blank'>Buprenorphine</a></li>
                                                        <li><a href="../../regulations/guidance.aspx">Guidance to OTPs</a></li>
                                                        <li><a href="../../regulations/regindex.aspx">...more</a></li>
                                                    </ul>
                                                </li>
                                                <li><a href="../medsindex.aspx">Pharmacotherapy</a>
                                                    <ul>
                                                        <li><a href="http://buprenorphine.samhsa.gov/" onclick='alert("You are about to leave the DPT Web site. The page you have requested will open in a new window. Close the new window to return to the DPT Web site.");'
                                                            target='_blank'>Buprenorphine</a></li>
                                                        <li><a href="../methadone.aspx">Methadone</a></li>
                                                        <li><a href="../naltrexone.aspx">Naltrexone</a></li>
                                                        <li><a href="../medsindex.aspx">...more</a></li>
                                                    </ul>
                                                </li>
                                                <li><a href="../../comor/comorindex.aspx">Co-morbidities</a>
                                                    <ul>
                                                        <li><a href="../../comor/hepatitis.aspx">Hepatitis</a></li>
                                                        <li><a href="../../comor/hivaids.aspx">HIV/AIDS</a></li>
                                                        <li><a href="../../comor/Co-occuring.aspx">Co-Occurring Disorders</a></li>
                                                        <li><a href="../../comor/comorindex.aspx">...more</a></li>
                                                    </ul>
                                                </li>
                                                <li><a href="../../treatment/treatmentindex.aspx">Find Treatment </a>
                                                    <ul>
                                                        <li><a href="../../treatment/treatmentindex.aspx">Find Treatment in Your
                                                            Area</a></li>
                                                    </ul>
                                                </li>
                                                <li><a href="../../patients/patientsindex.aspx">Patient &amp; Family Resources</a>
                                                    <ul>
                                                        <li><a href="../../patients/mat.aspx">About MAT</a></li>
                                                        <li><a href="../../patients/support.aspx">Support Organizations</a></li>
                                                        <li><a href="../../patients/patientsindex.aspx">...more</a></li>
                                                    </ul>
                                                </li>
                                                <li><a href="../../providers/providerindex.aspx">Provider Resources</a>
                                                    <ul>
                                                        
                                                             <li><a href="../../providers/OTPmortalityreport.aspx">OTP Mortality Report</a></li>
                                                        <li><a href="../../providers/providertraining.aspx">Provider Training</a></li>
                                                        <li><a href="http://www.nattc.org/index.html" onclick='alert("You are about to leave the SAMHSA Web site. SAMHSA provides links to other Internet sites as a service to its users, and is not responsible for the availability or content of these external sites. SAMHSA, its employees, and contractors do not endorse, warrant, or guarantee the products, services, or information described or offered at these other Internet sites. Any reference to a commercial product, process, or service is not an endorsement or recommendation by the SAMHSA, its employees, or contractors. For documents available from this server, the U.S. Government does not warrant or assume any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed.");'
                                                            target="_blank">Addiction Technology Transfer Centers</a></li>
                                                        <li><a href="../../providers/providerindex.aspx">...more</a></li>
                                                    </ul>
                                                </li>
                                                <li><a href="../../about/about.aspx">About the Division of Pharmacologic
                                                    Therapies (DPT)</a></li>
                                            </ul>
                                        </div>
                                    </td>
                                </tr>
                            </table>
                        </td>
                        <td style="vertical-align: top; padding-left: 10px; padding-right: 10px;">
                            
    <a name="content" id="content"></a>
    <h1>
        Methadone-Associated Mortality:<br />
        Report of a National Assessment
    </h1>
    <br />
    <h1>
        <a name="P224_52669"></a>Part 7. References and Bibliography</h1>
   
        <p>
            Appel PW. Joseph H, Richman BL. Causes and rates of death among methadone maintenance
            patients before and after the onset of the HIV/AIDS epidemic. Mt Sinai J Med. <b>2000</b>;67(5-6):444-451.
            <br />
            <br />
            Associated Press. Overdose increases linked to methadone. Stuart News (Stuart, Florida).
            October 4, <b>2002</b>.
            <br />
            <br />
            Backmund M, Meyer K, Von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection
            in injection drug users. Hepatology. <b>2001</b>;34(1):188-193.
            <br />
            <br />
            Backmund M, Meyer K, Zwehl W, Nagengast O, Eichenlaub D. Myocardial infarction associated
            with methadone and/or dihydrocodeine. Eur Addict Res. <b>2001a</b>;7(1):37-39.
            <br />
            <br />
            Baden MM. Evaluation of deaths in methadone users. Leg Med Annu. <b>1978</b>;127-31.
            <br />
            <br />
            Baden MM. Methadone related deaths in New York City. Int J Addict. <b>1970</b>;5(3):489-498.
            <br />
            <br />
            Ballesteros MF, Budnitz DS, Sanford CP, Gilchrist J, Agyekum GA, Butts J. Increase
            in deaths due to methadone in North Carolina [research letter]. JAMA. <b>2003</b>;290(1):40.
            <br />
            <br />
            Barrett DH, Luk AJ, Parrish RG, Jones TS. An investigation of medical examiners
            cases in which methadone was detected, Harris County, Texas, 1987-1992. J Forensic
            Sci, JFSCA. <b>1996</b>;41(3):442-448.
            <br />
            <br />
            Barton WI. Deaths involving methadone: A statistician's view. Drug Forum. <b>1975</b>;4(2):139-158.
            <br />
            <br />
            Bartu EE, Popescu A, Heutt KF, Hansson R, Plumley N. Methadone-related deaths in
            Western Australia 1993-99. Aust NZ J Pub Health. 2002;26(4):364-370.
            <br />
            <br />
            Bell J, Zador D. A risk-benefit analysis of methadone maintenance treatment. Drug
            Saf. <b>2000</b>;22(3)179-190.
            <br />
            <br />
            Belluck P. Methadone, once the way out, suddenly grows as killer drug. New York
            Times (National Edition). New York Times. February 9, <b>2003A</b>: 1,20.
            <br />
            <br />
            Belluck P. Overdoses and deaths from abuse of drug methadone are up. New York Times.
            February 2, <b>2003B</b>.<br />
            <br />
            Belluck P. Recently for drug abusers, methadone has become a double-edged sword.
            New York Times (National Edition). February 9, <b>2003C</b>: 20.
            <br />
            <br />
            Bendavid, N. Survey of drugs in Cook County: 333,000 labeled hard-core users. Chicago
            Tribune. December 12, <b>1997</b>;sec 1:1.
            <br />
            <br />
            Bittar P, Piguet V, Kondo-Oestreicher J, et al. Methadone induced long QTc and &quot;torsade
            de pointe.&quot; Swiss Medical Forum (Forum Med Suisse). <b>2002</b>(Apr 10, Suppl
            8):36S. [Abstract P244.]
            <br />
            <br />
            Borron SW, Monier C, Risede P, Baud FJ. Interaction of opiates with benzodiazepines
            in overdoses. J Toxicology:Clin Toxicology. <b>2001</b>;39(3):212.
            <br />
            <br />
            Bowler GM, Galloway DW, Meiklejohn BH, and Macintyre CC. Sharp fall in blood pressure
            after injections of heparin containing chlorbutanol. Lancet. <b>1986</b>;1:848-849.<br />
            <br />
            Brown FM, Griffiths PS. P450 Guide: Comprehensive Enzymatic Drug Metabolism Reference.
            2nd ed. Montgomery, AL: P450Guide.com; <b>2000</b>.<br />
            <br />
            Bruera E. Opioid rotation, methadone urged for hard-to-treat cancer pain. Presentation
            at 14th international meeting of MASCC. In: Oncology News International. <b>2002</b>;11(12):55.
            <br />
            <br />
            Cairns A, Roberts IS, Benbow EW. Characteristics of fatal methadone overdose in
            Manchester, 1985-94. BMJ. <b>1996</b>;313(7052):264-265.
            <br />
            <br />
            Caplan YH, Ottinger WE, Crooks CR. Therapeutic and toxic drug concentrations in
            post mortem blood: A six year study in the State of Maryland. J Anal Toxicol. <b>1983</b>;7(5):225-230.<br />
            <br />
            Caplehorn JRM. Deaths in the first two weeks of maintenance treatment in NSW in
            1994: Identifying cases of iatrogenic methadone toxicity. Drug and Alcohol Review.
            <b>1998</b>;17:9-18.<br />
            <br />
            Caplehorn JRM, Drummer OH. Mortality associated with New South Wales methadone programs
            in 1994: Lives lost and saved. Med J Aust. <b>1999</b>;170(3):104-109.
            <br />
            <br />
            CDHAG (Commonwealth Department of Health and Aged Care). Induction and Stabilisation
            of Patients Onto Methadone. Monograph Series No. 39. Canberra: Commonwealth of Australia;
            <b>2000</b>. Available at <a href="http://www.health.gov.au">http://www.health.gov.au</a>.
            <br />
            <br />
            Chang A, Emmel DW, Rossi GC, Pasternak GW. Methadone analgesia in morphine-insensitive
            CXBK mice. Eur J Pharm. <b>1988</b>;351:189-191.<br />
            <br />
            Codd E, Shank R, Schupsky J, Raffia R. Serotonin and norepinephrine uptake inhibiting
            activity of centrally acting analgesics: structural determinants and role in antinociception.
            J Pharmacol Exp Ther. <b>1995</b>;274:1263-1270.
            <br />
            <br />
            Clark JC, Milroy CM, Forrest ARW. Deaths from methadone use. J Clin For Med. <b>1995</b>;2:143-144.
            <br />
            <br />
            COMPA (New York State Committee of Methadone Program Administrators). Regarding
            Methadone Treatment and Other Pharmacotherapies: A Review. New York, NY: COMPA;
            revised <b>1999</b>. See also: <a href="http://www.compa-ny.org">http://www.compa-ny.org</a>.
            <br />
            <br />
            Concool B, Smith H, Stimmel B. Mortality rates of persons entering methadone maintenance:
            A seven-year study. Am J Drug Alcohol Abuse. <b>1979</b>;6(3):345-353.
            <br />
            <br />
            Cone EJ, Fant RV, Rohay JM. Oxycodone involvement in drug abuse deaths: A DAWN-base
            classification scheme applied to an oxycodone postmortem database containing over
            1000 cases. J Analyt Tox. <b>2003</b>;27:57-67.<br />
            <br />
            Cozza KL, Armstrong SC. The Cytochrome P450 System: Drug Interaction Principles
            for Medical Practice. Washington, DC: American Psychiatric Publishing, Inc.;<b>2001</b>.
            <br />
            <br />
            D'Aunno T, Pollack HA. Changes in methadone treatment practices: Results from a
            national panel study, 1988-2000. JAMA. <b>2002 </b>Aug 21;288(7):850-6.
            <br />
            <br />
            Davis AM, Inturrisi CE. d-Methadone blocks morphine tolerance and N-Methyl-D-Aspartate
            (NMDA)-induced hyperalgesia. J. Pharmacol Exp Ther. <b>1999</b>;289:1048-1053.
            <br />
            <br />
            Davoli M, Perucci CA, Forastiere F, et al. Risk factors for overdose mortality:
            A case-control within a cohort of intravenous drug users. Int J Epidemiol. <b>1993</b>;22(2):273-277.<br />
            <br />
            Dole VP, Foldes F, Trigg H, et al. Methadone poisoning. NYS J Med. <b>1971</b>;71:541-543.
            <br />
            <br />
            Dole VP. Implications of methadone maintenance for theories of narcotic addiction.
            JAMA. <b>1988</b>;260:3025-3029.<br />
            <br />
            Dorsey JS. Serum methadone levels and optimal dosing in methadone maintained patients.
            Poster presented at: American Association for the Treatment of Opioid Dependence
            Conference; April 13-16, <b>2003</b>; Washington, DC. Poster P9.
            <br />
            <br />
            Drasch G, Quitterer D, Roider G, Von Meyer L. The enantioselective detection of
            L- and D-methadone in blood samples from living and deceased addicts [German, abstract
            in English]. Rechtsmedizin. <b>2000</b>;10(5):170-175.<br />
            <br />
            Drummer OH, Opeskin K, Syrjanen M, Cordner SM. Methadone toxicity causing death
            in ten subjects starting on a methadone maintenance program. Am J Forensic Med Pathol.
            <b>1992</b>;13(4):346-350.<br />
            <br />
            Drummer OH, Syrjanen M, Opeskin K, Cordner SM. Deaths of heroin addicts starting
            on a methadone maintenance programme. Lancet. <b>1990</b>;335(8681):108.
            <br />
            <br />
            Drummer OH. The toxicology of methadone and its involvement in sudden death. In:
            35th Annual TIAFT (The International Association of Forensic Toxicologists) Conference.
            Padua, Italy; <b>1997</b>. Abstract 020.<br />
            <br />
            Eap CB, Bourquin M, Martin J-L, et al. Plasma concentrations of the enantiomers
            of methadone and therapeutic response in methadone maintenance treatment. Dru Alcohol
            Dep. <b>2000</b>;6(11):47-54.<br />
            <br />
            Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics
            of methadone: Implications for the treatment of opioid dependence. Clin Pharmacokin.
            <b>2002</b>;41(14):1153-1193.<br />
            <br />
            Eap CB, D&eacute;glon J-J, Baumann P. Pharmacokinetics and pharmacogenetics of methadone:
            Clinical relevance. Heroin Add &amp; Rel Clin Probl <b>1999</b>;1(1):19-34.
            <br />
            <br />
            Eap CB, Finkbeiner T, Gastpar M, Schebaum N, Bertschy G, Baumann P. High inter-individual
            variability of methadone enantiomer blood levels to dose ratios [letter]. Arch Gen
            Psychiatry <b>1988</b>;55:89-90.<br />
            <br />
            Eastwood JA. Methadone poisoning in children. SOFT-TIAFT 1998 (Society of Forensic
            Technologists-The International Association of Forensic Toxicologists) Albuquerque,
            New Mexico; October 7, <b>1998</b>. Scientific Session 1.
            <br />
            <br />
            Editorial. Medicine or menace? The Washington Times. February 19, <b>2003</b>.
            <br />
            <br />
            Editorial. Methadone overdoses: Abuse of drug spreading so let's restrict the amount.
            Portland Press Herald (Portland, Maine). September 18, <b>2002</b>.
            <br />
            <br />
            Ehlers S. U.S. Congress ponders anti-methadone bill [press release]. Washington,
            DC: Drug Policy Foundation; February 19, <b>1999</b>.<br />
            <br />
            English DR, Holman CDJ, Milne E, et al. The quantification of drug-caused morbidity
            and mortality in Australia, 1995 edition. Canberra: Commonwealth Department of Human
            Services and Health. AGPS. <b>1995</b>:539-542.
            <br />
            <br />
            Ettinger DS, Vitale PJ, Trump DL. Important clinical pharmacologic considerations
            in the use of methadone in cancer patients. Cancer Treat Rep. <b>1979</b>;63(3):457-459.
            <br />
            <br />
            Federal Register. Narcotic drugs in maintenance and detoxification treatment of
            narcotic dependence; Repeal of current regulations and proposal to adopt new regulations.
            Federal Register. July 22, <b>1999</b>;64(140):39809-39857. 21 CFR Part 291; 42
            CFR Part 8. Available from the Federal Register Online via GPO at: <a href="http://www.access.gpo.gov/su_docs">
                http://www.access.gpo.gov/su_docs</a>. Accessed August 1, 1999.<br />
            <br />
            Federal Register. Opioid drugs in maintenance and detoxification treatment of opiate
            addiction; Final rule. <b>2001 </b>(Jan 17);66(11):4085. 42 CFR Part 8.<br />
            <br />
            FDLE (Florida Department of Law Enforcement). 2002 Interim Report of Drugs Identified
            in Deceased Persons by Florida Medical Examiners. November <b>2002</b>. Available
            at: <a href="http://www.fdle.state.fl.us/publications/examiner_drug_report_2002.pdf">
                http://www.fdle.state.fl.us/publications/examiner_drug_report_2002.pdf</a>.
            <br />
            <br />
            Fingerhut LA, Cox CS. Poisoning Mortality, 1985-1995. Pub Health Rep. <b>1998</b>;113(3):218-233<br />
            <br />
            Flanagan RJ, Rooney C. Recording acute poisoning deaths. Forensic Sci Int. <b>2002</b>;128:3-19.<br />
            <br />
            Foster DJR, Somogyi AA, Bochner F. Methadone N-demethylation in human liver microsomes:
            lack of stereoselectivity and involvement of CYP3A4. Br J Clin Pharmacol <b>1999</b>;47:403-412.<br />
            <br />
            Frost JL. Commentary on: Oxycodone involvement in drug abuse deaths: A DAWN-base
            classification scheme applied to an oxycodone postmortem database containing over
            1000 cases. J Analyt Tox. <b>2003</b>;27:67.<br />
            <br />
            GAO (General Accounting Office). Methadone maintenance: some treatment programs
            are not effective; greater Federal oversight needed. Report to the chairman, Select
            Committee on Narcotics Abuse and Control, House of Representatives. Washington,
            DC: U.S. General Accounting Office; <b>1990</b>. Pub# GAO/HRD-90-104.
            <br />
            <br />
            Gardner R, Methadone misuse and death by overdosage. Br J Addict. <b>1970</b>; 65(2):113-118.<br />
            <br />
            Gearing FR, Schweitzer MD. An epidemiologic evaluation of long-term methadone maintenance
            treatment for heroin addiction. Am J Epidemiology. <b>1974</b>;100:101-111.
            <br />
            <br />
            Gfroerer J, Penne M, Pemberton M, Folsom R. Substance abuse treatment need among
            older adults in 2020: The impact of the aging baby-boom cohort. Drug Alcohol Depend.
            <b>2003</b>;69(2):127-135.<br />
            <br />
            Glauser FL, Downie RL, Smith WR. Electrocardiographic abnormalities in acute heroin
            overdosage. Bull Narc. <b>1977</b>;29(1):85-89.<br />
            <br />
            Goldstein A, Herrera J. Heroin addicts and methadone treatment in Albuquerque: a
            22-year follow-up. Drug Alcohol Depend. <b>1995</b>;40(2):139-150.
            <br />
            <br />
            Gordon NB. The functional potential of the methadone maintained person. CDRWG Monograph
            #2. Chemical Dependency Research Working Group: The New York State Office of Alcoholism
            and Substance Abuse Services. December <b>1994</b>:43-46.
            <br />
            <br />
            Gorman AL, Elliott KJ, Inturrisi CE. The d- and l- isomers of methadone bind to
            the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain
            and spinal cord, Nerurosci Lett. <b>1997</b>;223: 5-8.
            <br />
            <br />
            Gourevitch MN, Hartel D, Tenore P, et al. Three oral formulations of methadone.
            A clinical and pharmacodynamic comparison. J Subst Abuse Treat. <b>1999</b>;17(3):237-241.<br />
            <br />
            Gottheil E, Sterling RC, Weinstein SP. Diminished illicit drug use as a consequence
            of long-term methadone maintenance. J Addict Dis. <b>1993</b>;12(4):45-57.
            <br />
            <br />
            Green H, James RA, Gilbert JD, Harpas P, Byard RW. Methadone maintenance programs
            - A two-edged sword? Amer J For Med Path. <b>2000</b>;21(4):359-361.
            <br />
            <br />
            Greene MH, Luke JL, DuPont RL. Opiate overdose deaths in the District of Columbia.
            II. Methadone-related fatalities. J Forensic Sci. <b>1974</b>;19(3):575-584.
            <br />
            <br />
            Greenfield L, Fountain D. Influence of time in treatment and follow-up duration
            on methadone treatment outcomes. J Psychopath Behavioral Assess. <b>2000</b>;22(4):353-364.<br />
            <br />
            Haberman PW, Noble JA, DuFour MC. Alcohol use in combination with cocaine, heroin,
            and methadone by medical examiner cases. J Stud Alcohol. <b>1995</b>;56:344-347.
            <br />
            <br />
            Hampton CT. Long QT syndrome: more common than you thought. Clin Rev. <b>2003</b>;13(1):40-46.<br />
            <br />
            Hanzlick R. Death registration: history, methods, and legal issues. J Forensic Sci.
            <b>1997</b>;42(2):265-269.<br />
            <br />
            Hanzlick R, Hunsacker III JC, Davis GJ. A Guide for Manner of Death Classification.
            1st Edition. St. Louis, MO: National Association of Medical Examiners; February
            <b>2002</b>.<br />
            <br />
            Harding-Pink, D. Deaths associated with methadone. J Toxicol Clin Exp. <b>1991</b>;11(1):31-49.<br />
            <br />
            Harding-Pink D. Opioid toxicity. Lancet. <b>1993</b>;341:665-666.
            <br />
            <br />
            Heinemann A, Iwersen-Bergmann S, Stein S, Schmoldt A, Puschel K. Methadone-related
            fatalities in Hamburg 1990-1999: Implications for quality standards in maintenance
            treatment? Forensic Sci Int. <b>2000</b>;113(1-3):449-455.<br />
            <br />
            Heroin abuse and addiction. National Institutes on Drug Abuse (NIDA) Research Report
            Series. <b>1997 </b>(October). NIH Pub# 97-4165.<br />
            <br />
            Horrigan FT. Methadone block of neuronal K current. Biophysical J. <b>1990</b>;57:515A.
            Abstract W-Pos392.<br />
            <br />
            Hser Y-I, Grella CE, Anglin MD. A 33-year follow-up of narcotics addicts. Arch Gen
            Psychiatry. <b>2001</b>:58:503-508.<br />
            <br />
            Huber A, Ling W, Fradis J, Charuvastra VC. Comparison of the effects of methadone
            and LAAM on the electrocardiogram. Poster presented at: College of Problems of Drug
            Dependence (CPDD) 63rd Annual Scientific Meeting, Phoenix, AZ, June 20, <b>2001</b>.
            Also in: Huber A, Ling W, Fradis J, Charavastra VC. Comparison of the effects of
            methadone and LAAM on the electrocardiogram [abstract]. Drug Alcohol Depend. 2001;63:S70.<br />
            <br />
            Huidobro F, Tamayo L, Contreras E. Effects of methadone on the action of catecholamines
            in isolated preparations. Arch Int Pharmacodyn Ther. <b>1971</b>;192:168-178.
            <br />
            <br />
            Inturrisi CE, Verebely K. A gas-liquid chromatographic method for the quantitative
            determination of methadone in human plasma and urine. J Chrmatogr. <b>1972a</b>;65:361-369.<br />
            <br />
            Inturrisi CE, Verebely K. The levels of methadone in the plasma in methadone maintenance.
            Clin Pharm Ther. <b>1972b</b>;13(5 part 1):633-637.<br />
            <br />
            Joseph H, Appel P. Historical perspectives and public health issues. In: Parrino
            MW, chair. State Methadone Treatment Guidelines. Treatment Improvement Protocol
            (TIP) Series 1. Rockville, MD: U.S. Department of Health and Human Services; Center
            for Substance Abuse Treatment;<b>1993</b>:11-24 DHHS Pub# (SMA) 93-1991.<br />
            <br />
            Joseph H, Stancliff S, Langrod J. Methadone maintenance treatment (MMT): A review
            of historical and clinical issues. Mt Sinai J Med. <b>2000</b>;67(5-6):347-364.
            <br />
            <br />
            Joseph H, Woods JS eds. Methadone Treatment Works: A Compendium for Methadone Maintenance
            Treatment. CDRWG Monograph Series #2. Chemical Dependency Research Working Group:
            The New York State Office of Alcoholism and Substance Abuse Services. December <b>1994</b>.
            Available at: <a href="http://users.rcn.com/nama.interport/mono2.htm">http://users.rcn.com/nama.interport/mono2.htm</a>.
            Accessed May 23, 2002.<br />
            <br />
            Kallan JE. Drug abuse-related mortality in the United States: Patterns and correlates.
            Amer J Drug Alcohol Abuse. <b>1998</b>;24(1):103-117.
            <br />
            <br />
            Karch SB. Stephens BG. Toxicology and the pathology of deaths related to methadone:
            Retrospective review. West J Med. <b>2000</b>;172:11-14.
            <br />
            <br />
            Katchman AN, McGroary KA, Kilborn MJ, Kornick CA, Manfredi PL, Woosley RL, Ebert
            SN. Influence of opioid agonists on cardiac human <i>ether-a-go-go</i>-related gene
            K<sup>+</sup> currents. J Pharm Exp Ther. <b>2002</b>;303(3):688-694.
            <br />
            <br />
            Kauffman JF, Woody GE. Matching Treatment to Patient Needs in Opioid Substitution
            Therapy. Treatment Improvement Protocol (TIP) Series 20. Rockville, MD: U.S. Department
            of Health and Human Services; Center for Substance Abuse Treatment;<b>1995</b>.
            DHHS Pub# (SMA) 95-3049.<br />
            <br />
            Kocheril AG, Bokhari SA, Batsford WP, Sinusas AJ. Long QTc and torsades de pointes
            in human immunodeficiency virus disease. Pacing Clin Electrophysiol. <b>1997</b>;20(11):2810-2816.<br />
            <br />
            Kramer T. Side effects and therapeutic effects. Medsacape Gen Med. <b>2003</b>;5(1).
            Available at <a href="http://www.medscape.com">http://www.medscape.com</a>.<br />
            <br />
            Krantz MJ, Lewkowiez L, Hays H, et al. Torsade de pointes associated with very-high-dose
            methadone. Ann Intern Med. <b>2002</b>;137:501-504.
            <br />
            <br />
            Kreek MJ. A personal retrospective and prospective viewpoint. In: Parrino MW. State
            Methadone Treatment Guidelines. Treatment Improvement Protocol (TIP) Series 1. Rockville,
            MD: U.S. Department of Health and Human Services; Center for Substance Abuse Treatment;<b>1993</b>:133-143.
            DHHS Pub# (SMA) 93-1991.
            <br />
            <br />
            Kreek MJ, Gutjahr CL, Garfield JW, Bowen DV, Field FH. Drug interactions with methadone.
            Ann NY Acad Sci. <b>1976</b>;281:350-370.<br />
            <br />
            Kreek MJ, Hachey DL, Klein PD. Stereoselective disposition of methadone in man.
            Life Sci. <b>1979</b>;24:925-932.<br />
            <br />
            Kreek MJ. Medical safety and side effects of methadone in tolerant individuals.
            JAMA. <b>1973a</b>;223:665-668.<br />
            <br />
            Kreek MJ. Plasma and urine levels of methadone. NY State J Med. <b>1973b</b>;73(23):2773-2777.
            <br />
            <br />
            Kreek MJ. Rationale for maintenance pharmacotherapy of opiate dependency. In: O'Brien
            CP, Jaffe JH. Addictive States. New York, NY: Raven Press, Ltd.; <b>1992</b>:205-229.<br />
            <br />
            Kringsholm B. Deaths among drug addicts in Denmark in 1968-1986. Forensic Sci Int.
            <b>1988</b>;38(1-2):139-149.<br />
            <br />
            Kringsholm B, Kaa E, Steentoft A, Worm K, Simonsen KW. Deaths among drug addicts
            in Denmark in 1987-1991. Forensic Sci Int. <b>1994</b>;67(3):185-195.
            <br />
            <br />
            Kung H-C, Hanzlick R, Spitler JF. Abstracting data from medical examiner/coroner
            reports: Concordance among abstractors and implications for data reporting. J Forensic
            Sci. <b>2001</b>;46(5):1126-1131.<br />
            <br />
            La Harpe R, Fryc O. Fatalities associated with methadone administration in the Geneva
            canton (1987-1993). Arch Kriminol. <b>1995</b>;196(1-2):24-29.
            <br />
            <br />
            Leavitt SB. Does methadone maintenance treatment affect heart health? Addiction
            Treatment Forum: Special Report (peer reviewed). June <b>2001</b>. Available at:
            <a href="http://www.atforum.com">http://www.atforum.com</a>.<br />
            <br />
            Leavitt SB, Shinderman M, Maxwell S, Eap CB, Paris P. When &quot;enough&quot; is
            not enough: New perspectives on optimal methadone maintenance dose. Mt Sinai J Med.
            <b>2000</b>;67(5-6):404-411.<br />
            <br />
            Lee CH, Berkowitz BA. Calcium antagonist activity of methadone, l-acetylmethadol
            and l-pentazocine in the rat aortic strip. J Pharmacol Exp Ther. <b>1977</b>;202(3):646-653.
            <br />
            <br />
            Lehder DM, Arria A, Artigiani EE, Wish ED. Alcohol and drug-related overdose deaths
            in Maryland: 1997-2001. College Park, MD; Center for Substance Abuse Research (CESAR),
            University of Maryland: November <b>2002</b>. Available at <a href="http://www.dewsonline.org">
                http://www.dewsonline.org</a>.<br />
            <br />
            Leshner AI. Drug abuse research helps curtail the spread of deadly infectious diseases.
            NIDA Notes. <b>1999</b>;14(2):3-4. NIH Pub# 99-3478.<br />
            <br />
            Litovitz TL, Klein-Schwartz W, Rodgers GC, et al. 2001 annual report of the American
            Association of Poison Control Centers Toxic Exposure Surveillance System. Amer J
            Emergency Med. <b>2002</b>;20(5):391-452.<br />
            <br />
            Lobert S. Methadone may be a useful alternative for cancer pain. Oncology Nurs Forum.
            <b>2003</b>;30(1):21.<br />
            <br />
            Loimer N, Schmid R. The use of plasma levels to optimize methadone maintenance treatment.
            Drug Alcohol Depend <b>1992</b>;30(3):241-246.<br />
            <br />
            Magura S. Rosenblum A. Leaving methadone treatment: lessons learned, lessons forgotten,
            lessons ignored. Mt Sinai J Med. <b>2001</b>;68(1):62-74.
            <br />
            <br />
            Mallinckrodt Inc. Methadose&#174; Oral Concentrate (Methadone hydrochloride oral
            concentrate USP) [package insert]. St. Louis, MO: Mallinckrodt Inc; <b>2000</b>.
            <br />
            <br />
            Mallinckrodt Inc. Methadose&#174; Oral Tablets (Methadone hydrochloride tablets
            USP; 5, 10, 40 mg) [package inserts]. St. Louis, MO: Mallinckrodt Inc; <b>1995</b>.<br />
            <br />
            Manfredi PL, Foley KM, Payne R, Inturrisi CE, Houde R. Parenteral methadone: An
            essential medication for the treatment of pain. In progress, <b>2003</b>.
            <br />
            <br />
            Mantelli L, Corti V, Bini R, Cerbai E, Ledda F. Effects of dl-methadone on the response
            to physiological transmitters and on several functional parameters of the isolated
            guinea-pig heart. Arch Int Pharmacodyn Ther. <b>1986</b>;282(2):298-313.
            <br />
            <br />
            Marsch LA. The efficacy of methadone maintenance interventions in reducing illicit
            opiate use, HIV risk behavior and criminality: A meta-analysis. Addiction. <b>1998</b>;93(4):515-532.<br />
            <br />
            Martell BA, Arnstein JH, Ray B, Gourevitch MN. The impact of methadone induction
            on cardiac conduction in opioid users. Poster presented at: American Association
            for the Treatment of Opioid Dependence Conference; April 13-16, <b>2003</b>; Washington,
            DC. Poster P16.<br />
            <br />
            Mathot F, Kurz X, Noel C, Firket P. Long QTc and psychotropic drugs use. Int J Neuropsychopharmacology.
            <b>2002</b>;3(Suppl 1):S173. [Abstract P.02.18.]<br />
            <br />
            McCaffrey BR. Heroin access spurs need for methadone. USA Today. January 25, <b>1999</b>.<br />
            <br />
            Merrill J. Garvey T, Rosson C. Methadone concentrations taken as indicating deaths
            due to overdose need to be reviewed [letter]. BMJ. <b>1996</b>;313:1481.
            <br />
            <br />
            Mikolaenko I, Robinson A, Davis GG. A review of methadone deaths in Jefferson County,
            Alabama. J For Med Path. <b>2002</b>;23(3):299-304.
            <br />
            <br />
            Milroy CM, Forrest ARW. Methadone deaths: A toxicological analysis. J Clin Pathol.
            <b>2000</b>;53:277-281.<br />
            <br />
            Moody DE, Alburges ME, Parker RJ, Collins JM, Strong JM. The involvement of cytochrome
            P450 3A4 in the <i>N</i>-demethylation of <i>L</i>-_-acetylmethadol (LAAM), norLAAM,
            and methadone. Drug Metab Disp. <b>1997</b>;25(12):1347-1353.
            <br />
            <br />
            Nakamura K, Hachey DL, Kreek MJ, Irving CS, Klein PD. Quantitation of methadone
            enantiomers in humans using stable isotope-labeled [<sup>2</sup>H<sub>3</sub>]-,
            [<sup>2</sup>H<sub>5</sub>]-, and [<sup>2</sup>H<sub>8</sub>]methadone. J Pharm
            Sci. <b>1982</b>;71(1):40-43.<br />
            <br />
            NCHS (National Center for Health Statistics). International Classification of Diseases,
            Tenth Revision (ICD-10). Available at: <a href="http://www.cdc.gov/nchs/about/major/dvs/icd10des.htm">
                http://www.cdc.gov/nchs/about/major/dvs/icd10des.htm</a>. Updated <b>2002</b>.<br />
            <br />
            Neeleman J, Farrell M. Fatal methadone and heroin overdoses: time trends in England
            and Wales. Journal of Epidemiology and Community Health. <b>1997</b>; 51:435-437.<br />
            <br />
            NIDA (National Institute on Drug Abuse). Infectious diseases and drug abuse. NIDA
            Notes. <b>1999</b> (August);14(2):15. NIH pub #99-3478.
            <br />
            <br />
            NIH (National Institutes of Health). Effective Medical Treatment of Opiate Addiction.
            NIH Consensus Statement. Bethesda, MD: National Institutes of Health; <b>1997</b>(Nov
            17-19);15(6):1-38. (See also: JAMA. 1998;280:1936-1943.)
            <br />
            <br />
            Novick DM, Richman BL, Friedman JM, et al. The medical status of methadone maintained
            patients in treatment for 11-18 years. Drug Alcohol Dep. <b>1993</b>;33:235-245.
            <br />
            <br />
            Okruhlica L, Devinsk F, Valentova J, Klempova D. Does therapeutic threshold of methadone
            concentration in plasma exist? Heroin Add &amp; Rel Clin Probl. <b>2002</b>;4(1):29-36.<br />
            <br />
            Oliver P, Keen J, Mathers N. Deaths from drugs of abuse in Sheffield 1997-1999:
            What are the implications for GPs prescribing to heroin addicts? Fam Pract. <b>2002</b>;19(1):93-94.<br />
            <br />
            ONDCP (Office of National Drug Control Policy). Drug Abuse in America [slide presentation].
            Washington, DC: Office of National Drug Control Policy; <b>2002</b>. Available at:
            <a href="http://www.whitehousedrugpolicy.gov">http://www.whitehousedrugpolicy.gov</a>.<br />
            <br />
            ONDCP (Office of National Drug Control Policy). Policy Paper: Opioid Agonist Treatment.
            Washington, DC: Office of National Drug Control Policy; <b>1999</b> (March).<br />
            <br />
            ONDCP (Office of National Drug Control Policy). Methadone Fact Sheet. Washington,
            DC: Office of National Drug Control Policy; <b>2000</b> (April). Available at: <a
                href="http://www.whitehousedrugpolicy.gov">http://www.whitehousedrugpolicy.gov</a>.<br />
            <br />
            ONDCP (Office of National Drug Control Policy). President's National Drug Control
            Strategy 2003. Washington, DC: Office of National Drug Control Policy; <b>2003</b>
            (February). Available at: <a href="http://www.whitehousedrugpolicy.gov">http://www.whitehousedrugpolicy.gov</a>.
            <br />
            <br />
            Parrino MW. The renaissance of methadone treatment in America. J Maintenance in
            the Addictions. <b>2003</b>;2(1/2):5-17.<br />
            <br />
            Payte JT. A brief history of methadone in the treatment of opioid dependence: a
            personal perspective. J Psychoactive Drugs. <b>1991</b>;23(2):103-107.
            <br />
            <br />
            Payte JT, Khuri ET, Joseph H, Woods J. The methadone maintained patient and the
            treatment of pain. CDRWG Monograph #2. Chemical Dependency Research Working Group:
            The New York State Office of Alcoholism and Substance Abuse Services. <b>1994</b>:
            35-40.<br />
            <br />
            Payte JT, Khuri ET. Principles of methadone dose determination. In: Parrino MW.
            State Methadone Treatment Guidelines. Treatment Improvement Protocol (TIP) Series
            1. Rockville, MD: U.S. Department of Health and Human Services; Center for Substance
            Abuse Treatment;<b>1993a</b>:47-58 DHHS Pub# (SMA) 93-1991.
            <br />
            <br />
            Payte JT, Khuri ET. Treatment duration and patient retention. In: Parrino MW. State
            Methadone Treatment Guidelines. Treatment Improvement Protocol (TIP) Series 1. Rockville,
            MD: U.S. Department of Health and Human Services; Center for Substance Abuse Treatment;<b>1993b</b>:119-124.
            DHHS Pub# (SMA) 93-1991.
            <br />
            <br />
            Payte JT, Zweben JE. Opioid maintenance therapies. In: Graham AW, Schultz TK, eds.
            Principles of Addiction Medicine. 2nd ed. Chevy Chase, MD: American Society of Addiction
            Medicine, Inc; <b>1998</b>:557-570.<br />
            <br />
            Perret G, Deglon JJ, Kreek MJ, Ho A, La Harpe R. Lethal methadone intoxications
            in Geneva, Switzerland, from 1994 to 1998. Addiction. <b>2000</b>;95(11):1647-1653.
            <br />
            <br />
            Petry NM, Bickel WK, Badger GJ. A 12-year study (1975 - 1986) of mortality in methadone
            maintenance patients: Selected demographic characteristics and drug-use patterns
            of AIDS and non-AIDS-related deaths. Subst Use Misuse. <b>1998</b>; 33(12):2521-2534.<br />
            <br />
            Prouty RW, Anderson WH. The forensic science implications of site and temporal influences
            on postmortem blood-drug concentrations. J Forensic Sci. <b>1990</b>;35(2):243-270.<br />
            <br />
            Rendig SV, Amsterdam EA, Henderson GL, Mason DT. Comparative cardiac contractile
            actions of six narcotic analgesics: morphine, meperidine, pentazocine, fentanyl,
            methadone and l-alpha-acetylmethadol (LAAM). J Pharmacol Exp Ther. <b>1980</b>;215(1):259-265.<br />
            <br />
            Rettig RA, Yarmolonsky A (eds). Federal Regulation of Methadone Treatment. Committee
            on Federal Regulation of Methadone Treatment; Division of Biobehavioral Sciences
            and Mental Disorders; Institute of Medicine (IOM). Washington, DC: National Academy
            Press; <b>1995</b>.<br />
            <br />
            Robinson AE, Williams FM. The distribution of methadone in man. J Pharm Pharmac.
            <b>1971</b>;23:353-358.<br />
            <br />
            Roizin L, Helpern M, Baden M. Methadone fatalities in heroin addicts. Psychiatric
            Quart. <b>1972</b>;46(3):393-410.<br />
            <br />
            Rosenblum A, Magura S, Joseph H. Ambivalence toward methadone treatment among intravenous
            drug users. J Psychoactive Drugs. <b>1991</b>;23(1):21-
            <br />
            <br />
            Roxane Laboratories. Dolophine&#174; Hydrochloride (Methadone Hydrochloride Injection,
            USP) [package insert]. Manufactured by Eli Lilly and Company. Columbus, Ohio: Roxane
            Laboratories, Inc; May 26, <b>1995</b>.<br />
            <br />
            Roxane Laboratories. Methadone Hydrochloride IntensolTM (Oral Concentrate, USP 10
            mg/mL) [package insert]. Columbus, Ohio: Roxane Laboratories, Inc; Revised February
            <b>1998</b>.<br />
            <br />
            Roxane Laboratories. Methadone Hydrochloride Tablets USP [package insert]. Columbus,
            Ohio: Roxane Laboratories, Inc; Revised December <b>2000</b>.
            <br />
            <br />
            SAMHSA (Substance Abuse and Mental Health Services Administration). National Household
            Survey on Drug Abuse (NHSDA). <b>2001</b>. Available at <a href="http://www.samhsa.gov">
                http://www.samhsa.gov</a>.<br />
            <br />
            SAMHSA (Substance Abuse and Mental Health Services Administration). The Dawn Report.
            Narcotic Analgesics. January <b>2003</b>. Available at <a href="http://www.samhsa.gov">
                http://www.samhsa.gov</a>.
            <br />
            <br />
            SAMHSA (Substance Abuse and Mental Health Services Administration). Mortality Data
            From the Drug Abuse Warning Network, 2001. DAWN Series D-23, <b>2002</b>. DHHS Publication
            No. (SMA) 03-3781. Available at <a href="http://www.samhsa.gov">http://www.samhsa.gov</a>.
            <br />
            <br />
            Sanford C. Deaths from Unintentional Drug Overdoses in North Carolina, 1997-2001:
            A DHHS Investigation into Unintentional Poisoning-Related Deaths. NC Injury and
            Violence Prevention Unit. North Carolina Department of Health and Human Services.
            September 20, <b>2002</b>.<br />
            <br />
            Segal RJ, Catherman RL. Methadone - A cause of death. J Forensic Sci. <b>1974</b>;19(1):64-71.<br />
            <br />
            Seyler DE, Borowitz JL, Maickel RP. Calcium channel blockade by certain opioids.
            Fundam Appl Toxicol. <b>1983</b>;3(6):536-542.<br />
            <br />
            Sorg MH. Accidental methadone deaths in Maine 1997-2002. Slide presentation and
            handout October 7, <b>2002</b>.<br />
            <br />
            Sorg MH, Greenwald M. Maine Drug-Related Mortality Patterns:1997-2002. State of
            Maine; December 27, <b>2002</b>. (Report in cooperation with the Maine Office of
            the Attorney General and Maine Office of Substance Abuse.)
            <br />
            <br />
            Sporer KA. Acute heroin overdose. Ann Intern Med. <b>1999</b>;130:584-590.
            <br />
            <br />
            Squires T. National confidential enquiry into methadone related deaths (Scotland)
            2000. The Scottish Executive, Health Department, Clinical Resource and Audit Group
            (CRAG Ref 99/05); <b>2000</b>. Available at: <a href="http://www.show.scot.nhs.uk/crag/topics/mhealth/NCEMRD.doc">
                http://www.show.scot.nhs.uk/crag/topics/mhealth/NCEMRD.doc</a>.
            <br />
            <br />
            Stimmel B, Lipski J, Swartz M, Donoso E. Electrocardiographic changes in heroin,
            methadone and multiple drug abuse: A postulated mechanism of sudden death in narcotic
            addicts. Proc Natl Conf Methadone Treat. <b>1973</b>;1:706-710. Also in: Lipski
            J, Stimmel B, Donoso E. The effect of heroin and multiple drug abuse on the electrocardiogram.
            Amer Heart J. 1973;86(5):663-668 [This was an earlier analysis of the same methadone-maintained
            population].
            <br />
            <br />
            Stine SM, Meandzija B, Kosten TR. Pharmacologic therapies for opioid addiction.
            In: Graham AW, Schultz TK, eds. Principles of Addiction Medicine. 2nd ed. Chevy
            Chase, MD: American Society of Addiction Medicine, Inc; <b>1998</b>:545-555.
            <br />
            <br />
            Symanski JD, Gettes LS. Drug effects on the electrocardiogram. A review of their
            clinical importance. Drugs. <b>1993</b>;46(2):219-248.<br />
            <br />
            Takehana H, Izumi T. Alcoholic heart disease [Japanese, English abstract]. Nippon
            Rinsho. <b>2000</b>;58(1):151-156.<br />
            <br />
            Tomargo J. Drug-induced torsade de pointes: from molecular biology to bedside. Jpn
            J Pharmacol. <b>2000</b>;83:1-19.<br />
            <br />
            Valmana A, Oyefeso A, Clancy C, Ghodse H. Methadone-related deaths: Data from 18
            coroners' jurisdictions in England. Med Sci Law. <b>2000</b>;40(1):61-65.
            <br />
            <br />
            van Laar M, Crutis G, Vicente J, Frost N, Hartnoll R. EMCDDA standard protocol for
            the EU member states to collect data and report figures for the key indicator drug-related
            deaths by the standard reitox tables. EMCDDA Scientific Report 20-08-2002. Lisbon
            Portugal: European Monitoring Centre for Drugs and Drug Addiction; <b>2002</b>.
            Available at <a href="http://www.emcdda.eu.int">http://www.emcdda.eu.int</a>.
            <br />
            <br />
            White JM, Irvine RJ. Mechanisms of fatal opioid overdose. Addiction. <b>1999</b>;94(7):961-972.<br />
            <br />
            Williamson PA, Foreman KJ, White JM, Anderson G. Methadone-related overdose deaths
            in South Australia, 1984-1994. Med J Aust. <b>1997</b>;166:302-305.
            <br />
            <br />
            Wolff K. Characterization of methadone overdose: Clinical considerations and the
            scientific evidence. Ther Drug Monit. <b>2002</b>;24(4):457-470.
            <br />
            <br />
            Wolf K, Sanderson M, Hay AWM, Ralstrick D. Methadone concentrations in plasma and
            their relationship to drug dosage. Clin Chem. <b>1991</b>;37(2):205-209.
            <br />
            <br />
            Wu C, Fry CH, Henry JA. Membrane toxicity of opioids measured by protozoan motility.
            Toxicology. <b>1997a</b>;117:35-44.<br />
            <br />
            Wu C, Fry CH, Henry JA. The mode of action of several opioids on cardiac muscle.
            Exp Physiol. <b>1997b</b>;82:261-272.<br />
            <br />
            Wu C, Henry JA. Interaction between ethanol and opioids in a protozoan assay. Hum
            Exp Toxicol. <b>1994</b>;13:145-148.<br />
            <br />
            Zador D, Sunjic S, Darke S. Heroin-related deaths in New South Wales, 1992: Toxicological
            findings and circumstances. Med J Australia. <b>1996</b>;164:204-207.
            <br />
            <br />
            Zador D Sunjic S. Deaths in methadone maintenance treatment in New South Wales,
            Australia 1990-1995. Addiction. <b>2000</b>;95(1):77-84.<br />
            <br />
            Zanis DA, Woody GE. One-year mortality rates following methadone treatment discharge.
            Drug Alcohol Depend. <b>1998</b>;52(3):257-260.<br />
            <br />
            Zickler P. 33-year study finds lifelong, lethal consequences of heroin addiction.
            NIDA Notes. <b>2001</b>;16(4):1. NIH Publication No. 02-3478.
            <br />
            <br />
            Zweben JE, Payte JT. Methadone maintenance in the treatment of opioid dependence;
            A current perspective. West J Med. <b>1990</b>;152:588-599.</p>
    
    <br />
    <br />
    <a href="methadone_mortality-07.aspx">Previous Page</a> | <a href="methreports.aspx">
        Report Home</a> | <a href="methadone_mortality-09.aspx">Next Page</a>

                        </td>
                    </tr>
                </table>
                <!-- BEGIN FOOTER -->
                <table width="100%" class="noprint" >
                    <tr>
                        <td style="width: 29%;">
                            &nbsp;</td>
                        <td>
                            <br />
                            Note to users of screen readers and other assistive technologies: Please report
                            your problems
                            <br />
                            to us at <a href="mailto:otp-extranet@opioid.samhsa.gov">otp-extranet@opioid.samhsa.gov</a>.</td>
                    </tr>
                    <tr>
                        <td style="width: 100%" colspan="2">
                            <div id="footer">
                                <hr noshade="noshade" style="width: 100%; color: #999999; text-align: center; size: 1" />
                                <div id="btm_logo">
                                    <a href="http://www.hhs.gov" id="ctl00_A8" title="link to the Department of Health and Human Services">
                                        <img src="../../images/dhhs_logo.gif" alt="DHHS logo" style="text-align: left" width="87" height="79" /></a></div>
                                <p class="footer2">
                                    <a href="../../index.aspx">Home</a>&nbsp;&nbsp;&#8226;&nbsp;&nbsp;<a href="../../regulations/regindex.aspx">Regulations</a>&nbsp;&nbsp;&#8226;&nbsp;&nbsp;<a href="../medsindex.aspx">Pharmacotherapy</a>&nbsp;&nbsp;&#8226;&nbsp;&nbsp;<a href="../../comor/comorindex.aspx">Co-morbidities</a>&nbsp;&nbsp;&#8226;&nbsp;&nbsp;<a href="../../treatment/treatmentindex.aspx">Find Treatment</a>&nbsp;&nbsp;&#8226;&nbsp;&nbsp;<a href="../../patients/patientsindex.aspx">Patient Resources</a>&nbsp;&nbsp;&#8226;&nbsp;&nbsp;<a href="../../providers/providerindex.aspx">Provider Resources</a></p>
                                <p class="footer3">
                                    <a href="../../about/about.aspx">Contact Us</a> | <a href="http://www.samhsa.gov/about/508.aspx">
                                        Accessibility</a> | <a href="http://www.samhsa.gov/privacy.aspx">Privacy Policy</a>
                                    | <a href="http://www.samhsa.gov/foia/content/foia_main.html">FOIA</a> | <a href="http://www.samhsa.gov/about/Disclaimer.aspx">
                                        Disclaimers</a> | <a href="http://www.samhsa.gov/index.aspx">SAMHSA</a> | <a href="http://www.csat.samhsa.gov/">
                                            CSAT</a> | <a href="http://www.hhs.gov/">HHS</a> | <a href="http://www.USA.gov/">USA.gov</a>
                                    <br />
                                    <br />
                                </p>
                                <p class="contact">
                                    Department of Health and Human Services<br />
                                    Substance Abuse and Mental Health Services Administration, Center for Substance
                                    Abuse Treatment<br />
                                    Division of Pharmacologic Therapies<br />
                                    1 Choke Cherry Road&nbsp;&nbsp;&#8226;&nbsp;&nbsp;Room 2-1075&nbsp;&nbsp;&#8226;&nbsp;&nbsp;Rockville,
                                    MD 20857&nbsp;&nbsp;&#8226;&nbsp; 240-276-2700&nbsp;&nbsp;&#8226;&nbsp;&nbsp;<a href="mailto:otp@samhsa.hhs.gov">otp@samhsa.hhs.gov</a></p>
                                <br />
                                <br />
                            </div>
                        </td>
                    </tr>
                </table>
            </td>
        </tr>
    </table>

    <script src="http://www.google-analytics.com/urchin.js" type="text/javascript">
    </script>

    <script type="text/javascript">
_uacct = "UA-1575239-1";
urchinTracker();
    </script>

    <map name="map" id="map">
        <area shape="circle" coords="51,49,44" href="http://www.samhsa.gov" title="link to the Substance Abuse &amp; Mental Health Services Administration"
            alt="link to the Substance Abuse &amp; Mental Health Services Administration" />
        <area shape="rect" coords="678,27,810,85" href="../about/about.aspx" title="division of pharmacologic therapies logo" alt="division of pharmacologic therapies logo" />
    </map>
</body>
</html>
